Takeda Pharmaceutical Co Ltd
TAK
View Detailed Chart
15.165USD
+0.105+0.70%
Market hours （ET）Quotes delayed by 15 min
23.69BMarket Cap
0.17P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.70%
5 Days
-0.69%
1 Month
+1.10%
6 Months
+1.03%
Year to Date
+14.54%
1 Year
+3.16%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-15Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
18.333
Target Price
+21.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 287.84%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 287.84%.
Overvalued
The company’s latest PE is 0.17, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.78M shares, decreasing 8.33% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 3.71M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Ticker SymbolTAK
CompanyTakeda Pharmaceutical Co Ltd
CEOMr. Christophe Weber
Websitehttps://www.takeda.com/
Related Instruments
+2.74%
-0.35%
-0.35%
-0.17%
-0.07%
-0.01%
+3.78%
-0.50%
-0.88%
-0.10%
+0.98%
-0.91%
-0.08%
-0.74%
-3.77%
-0.25%
-0.02%
+0.99%
+0.97%
+0.15%
